Diffuse Midline Glioma — Trials

Diffuse Midline Glioma — Trials · CancerIndex

Clinical trials

Registered studies

129 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 61
Recruiting: 32
Ph III recruiting: 1
Growth YoY: —
Industry share: 18%
Top sponsor: Nationwide Children's Hospital
Termination share: 43.2%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (23)

clinicaltrialsPublishedShowing 1–3 of 3 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05476939	Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0(BIOMEDE 2)	recruiting	Phase 3	433	Gustave Roussy, Cancer Campus, Grand ParisOTHER	6	Aug 13, 2026	clinicaltrials
NCT04532229	Nimotuzumab in Combined With Chemoradiotherapy to Treat the Newly Diagnosed Diffuse Intrinsic Pontine Glioma in Children	unknown	Phase 3	48	Biotech Pharmaceutical Co., Ltd.OTHER	1	Jul 27, 2023